Erik Huestis Speaks with Pharmaceutical Executive About How Quantum Computing is Poised to Take Off in the Pharma Setting
February 15, 2024
Intellectual Property Partner Erik Huestis spoke with Pharmaceutical Executive about the use of quantum computing in the pharmaceutical setting. “The application in biotech is that it’s extremely computationally prohibitive to compute attributes of molecules and complex com-pounds in a classical regime, but quantum simulation and universal quantum computing allows us to compute those properties of pharmaceutically interesting molecules on a reasonable time scale with reasonable precision. That feeds directly into the discovery pipeline.”
We use cookies to enhance user experience, improve functionality and performance, and for analysis of website traffic. By clicking “accept”, you agree to the use of cookies. For more information about our cookie policy and the information we collect, please review our Privacy Statement.
Foley Hoag
Email Disclaimer
Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK," you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you.
If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Foley Hoag.
